3rd Annual Advances in Immuno-Oncology Congress
TBD LondonLondon, UK Visit the Venue to read more
3rd Annual Advances in Immuno-Oncology Congress is organized by Oxford Global Marketing Ltd and will be held during May 24 - 25, 2018 at London, England, United Kingdom.
Delegates will benefit from:
• An executive format providing intimate interaction with industry peers’ ideas and experiences through case study presentations and panel discussions
• Networking opportunities and sharing ideas with other senior peers
• Pre-scheduled one-to-one meetings between you and solution providers will provide you with an opportunity to forge partnerships and discover solutions
• Post-event follow up offering all documentation from the meeting and re-booking discounts
• Tailor-made agenda – hand pick any conference and panel sessions you wish to attend
Stefan Glück, Vice President Global Medical Affairs
Timothy Herpin, Vice President, Head of Transactions, Business Development
Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology
Kenneth Emancipator, Executive Medical Director and Head of Companion Diagnostics
Jianda Yuan, Senior Director, Translational Immuno-Oncolology Research
Sara Brett, Director Translational Immunology
Roman Kischel, Director Research – BiTE Technology
Maria Groves, Associate Director, Lab Head for the CRUK/MedImmune Alliance
Eric Hatterer, Head, In Vitro Pharmacology, ESTM Department
Krysztof Masternak, Head of Biology
Carola Ries, Head of Cancer Immunotherapy
Sophie Wildsmith, Diagnostic Expert; Oncology, Personalised Healthcare and Biomarkers
Grace Macaulay, Global Safety Physician, Patient Safety-Oncology
Troels Jordansen, Chief Executive Officer
Dolores Schendel, Chief Executive Officer & Chief Scientific Officer
Julio Castro, Chief Executive Officer
Bruce Roberts, Chief Scientific Officer
Frederic Triebel, Chief Scientific Officer & Chief Medical Officer
Agnete Fredriksen, Chief Scientific Officer
David Urech, Co-Chief Executive Officer and Chief Scientific Officer
Numab Therapeutics AG
Takashi Kishimoto, Chief Scientific Officer
Selecta Biosciences, Inc.
Geert Mudde, Chief Scientific Officer
Jonathan Pachter, Chief Scientific Officer
Igor Matushansky, Chief Medical Officer
Ely Benaim, Chief Medical Officer
Jonathan Zalevsky, Senior Vice President, Biology & Preclinical Development
James Legg, Vice President, R&D
Sreesha Srinivasa, Associate Vice President, Head – Translational Research
Biocon Research Ltd.
Tim Wyant, Senior Director of Cancer Immunology
Markus Zettl, Director, Immuno-Oncology
Joanne Bedwell-Garner, Development Director
Richard C. A. Sainson, Director of Pharmacology and Translational Sciences
Haining Huang, Director, Immuno-Oncology
Steven Shaw, Director of Translational Medicine
Wendy Broom, Associate Director, Discovery
Shimobi Onuoha, Associate Director, Binder Discovery
Patrik Kehler, Head of Immuno-Oncology
Tom Holdich, Head of Global Medical Affairs & EU Clinical Development
Philipp Mueller, Principal Scientist
Christoph Goletz, Senior Scientist, Immuno-Oncology
Paul Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology and Genetics
University of Wisconsin
Nelson Tang, Professor of Allergy and Immunology
Chinese University of Hong Kong
Awen Gallimore, Professor of Medicine
University of Cardiff
2017 Speakers Included:
Philip Arlen, President and CEO
Precision Biologics, Inc.
Alan Graham Pockley, Professor & Director
Nottingham Trent University, multimmune GmbH
Ulf Grawunder, CEO
Karen LaRochelle, Chief Business Officer
Jonathan Zalevsky, Vice President, Biology & Preclinical Development
Timothy Herpin, Vice President, Head of Transactions, Business Development
Jacqueline Doody, Vice President, Immunology
F-star Biotechnology Ltd.
Christopher Heery, Chief Medical Officer
Christophe Queva, Chief Scientific Officer
James Legg, Director
Pieter Fokko van Loo, Director
Markus Mohrs, Director, Immuno-Oncology
Marlon J. Hinner, Director of Immuno-oncology
Chan Whiting, Director of Immune Monitoring and Biomarker Development
Peter Dudek, Principal
Wellington Partners Life Science Venture Capital
Cedrik Britten, VP, Head of Oncology Cell Therapy DPU, Oncology R&D
Regina Heidenreich, Head of Immunotherapy
Guillaume Vignon, Global Head of Immuno-Oncology Licensing & Business Development
David Krige, Head of Biomarkers
Geert. C. Mudde, Founder and CSO
OncoQR ML GmbH
Nicolas Poirier, Chief Scientific Officer
Dan Williams, Head, UK Research Operations
Bruno Gomes, Head of Tumor Immunology
Alfonso Quintas, Global Clinical Leader, Oncology,
Novartis Institute for Biomedical Research
Saso Cemerski, Principal Scientist
Brian Haines, Principal Scientist in Vivo Pharmacology
MSD Research Laboratories
Matthew Albert, Principal Scientist, Cancer Immunology
Elena Brin, Research Fellow
Luca Melchiori, Group Leader, T Cell Correlate Research
Sara Colombetti, Group Leader
Roche Innovation Center Zürich
Mike Giffin, Senior Scientist
Pushpa Jayaraman, Investigator III
Novartis Institutes for BioMedical Research (NIBR)
Christian Schmees, Head of Tumor Biology
Ravi Madan, Clinical Director, Genitourinary Malignancies Branch
National Cancer Institute, National Institutes of Health
Lenny Shultz, Professor
The Jackson Laboratory
Paul M. Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics
University of Wisconsin
Hardev Pandha, Professor of Medical Oncology
University of Surrey
Winald Gerritsen, Professor of Tumour Immunotherapy
Radboud University Medical Centre Nijmegen
Silvia Formenti, Sandra and Edward Meyer Professor of Cancer Research, Chairman, Department of Radiation Oncology, Associate Director, Meyer Cancer Center
Weill Cornell Medical College
Sophia Karagiannias, Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine
King’s College London
Ahuva Nissim, Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology
Queen Mary University of London
Jeanette Leusen, Head Immunotherapy Group of the Laboratory for Translational Immunology
University Medical Center Utrecht
Dominic Eisinger, Vice President of Sales and Marketing
Steven M. Anderson, Senior Vice President
Marie Cumberbatch, Consultant to Histologix, Director
Immune Insight Limited
Alison O’Mahony, Vice President R&D Research Biology
Stephen Anderton, Chief Scientific Officer
Neil Williams, Founder and Chief Scientific Officer
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Oxford Global have been made aware of a service provider under the name Exhibition Housing Services (EHS), which has contacted a number of companies who are supporting or attending the Advances in Immuno-oncology Congress, to offer hotel reservation services.
Please note that Exhibition Housing Services do not represent Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to exhibitors.
If you are contacted by Exhibition Housing Services by phone or email using Oxford Global’s name or the name of the Advances in Immuno-oncology Congress and offering hotel reservation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by EHS or entering into any conversation with EHS or replying to any EHS emails sent from ‘@ehshousing.com’.
EHS offer a pre-paid hotel reservation service and we believe that exhibitors and attendees need to be extremely careful when dealing with EHS as a booking fee is charged in addition to the hotel price. In addition it appears that any credit cards used to secure bookings will be immediately used for taking 25% of value of booking and once any exhibitor or attendee have confirmed that he / she wishes to go ahead with the accommodation booking full payment is taken. EHS also operate very stringent cancellation policies.
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
How to submit your abstract
We will require:
Abstract (200 words or less)
In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.
To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, to register please click on book online or for more information please call +44 (0)1865 248455.
Oxford Global’s events are the perfect platform to stimulate lead generation, partnership formation, brand building and global business deals. They provide shortened sales cycles and measurable ROI.
Sponsorships are highly effective in enabling market immersion & visibility, direct access to existing clients and potential customers alongside dedicated face to face meeting time with important targets.
Alternatively, contact firstname.lastname@example.org
Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.
ImmunXperts, a young company with a rich history, offers services to support you in the risk assessment and mitigation of your drug candidate’s immunogenicity profile, the functional screening of your immuno-oncology candidates and the development of potency assays for stem cells. We also provide services for the isolation and cryopreservation of biological samples and we offer support and training with assay development. In collaboration with our scientific advisors and international partners, ImmunXperts offers access to a unique team of seasoned immunology experts. Our partnership model allows us to tap into a broad network of subcontractors and academic collaborators, resulting in a wide range of technologies and broad service offering. We think with you!
- Myriad RBM
Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner. All services are performed in our CLIA certified laboratory. As a guide to drug development researchers, Myriad RBM also offers Strategic Biomarker Services that include companion diagnostics, custom assay development, co-sponsored research programs, and innovative cell culture products. Myriad RBM’s biomarker testing laboratory is located in Austin, TX. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests.
ProQinase is a leading CRO for anti-cancer drug discovery providing customized solutions from primary compound screening to in vivo proof of concept. Apart from integrated drug discovery projects as a “one-stop shop” solution provider, ProQinase also carries out single service solutions.
A main focus of ProQinase’s expertise is a versatile immuno-oncology platform based on syngeneic mouse models (subcutaneous, orthotopic, metastasis) which can be analysed via flow cytometry, bioluminescence imaging, histology and further methods.
In addition, ProQinase offers xenograft mouse models as well as cell-based and biochemical assays. Our strengths are custom-tailored solutions for testing your drug or immunotherapeutic.
One of the latest innovative developments at ProQinase is a series of new tumor graft models from spontaneously arisen or carcinogen-induced malignant tissues (Carcinogen-Induced or Spontaneous Mouse-Derived Isografts, cMDI or sMDI, respectively). The tumors are propagated in mice only (i.e. without cell culture), and hence original tumor characteristics including original intratumoral immune cell populations are maintained
- Tissue Solutions
Ultivue’s proprietary reagents, instruments, and bioinformatics tools will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options. In 2017, the company is launching products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.
Contact No.: +44 (0)1865 248455